CN112826778A - Polypeptide and plant composition for inhibiting melanin synthesis - Google Patents
Polypeptide and plant composition for inhibiting melanin synthesis Download PDFInfo
- Publication number
- CN112826778A CN112826778A CN202110053395.1A CN202110053395A CN112826778A CN 112826778 A CN112826778 A CN 112826778A CN 202110053395 A CN202110053395 A CN 202110053395A CN 112826778 A CN112826778 A CN 112826778A
- Authority
- CN
- China
- Prior art keywords
- polypeptide
- extract
- composition
- plant
- palmitoyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9794—Liliopsida [monocotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
- A61K2800/5922—At least two compounds being classified in the same subclass of A61K8/18
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
- A61K2800/782—Enzyme inhibitors; Enzyme antagonists
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Dermatology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Cosmetics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention discloses a polypeptide and plant composition for inhibiting melanin synthesis and a preparation method thereof, wherein the polypeptide and plant composition comprises palmitoyl pentapeptide-4, palmitoyl tripeptide-1, palmitoyl tetrapeptide-7, palmitoyl tripeptide-5, nonapeptide-1, L-carnosine, hexapeptide-9, acetyl hexapeptide-8, pentapeptide-3, coix seed extract, cynomorium songaricum extract, astragalus extract, radix bupleuri extract and liquorice extract. The polypeptide and the plant composition are compounded, and the skin is whitened, repaired and anti-aging from multiple aspects by utilizing different mechanisms and sites of action of the polypeptide and the plant composition. The polypeptide and the plant extract have a synergistic effect, and the promotion effect on fibroblast proliferation is improved along with the increase of the types of the polypeptide and the addition of the plant extract. Meanwhile, the polypeptide is very safe, has homologous polypeptide components with human bodies, and is not easy to cause immune reaction and other side effects of the human bodies.
Description
Technical Field
The invention relates to the field of skin care, and particularly relates to a polypeptide and plant composition for inhibiting melanin synthesis.
Background
The skin is the largest organ of the human body and covers the surface of the human body to protect the human body. While the state of the skin will reflect the appearance of the individual. Healthy skin is smooth, glossy and elastic, which is also the skin condition sought by people. However, with the aging, ultraviolet irradiation, bad habit of work and rest, and the stimulation of emotional stress, the skin is easily aged and damaged, becomes rough, and loses luster and elasticity. Skin aging leads to pigmentation, formation of spots and appearance of skin problems such as wrinkles, sagging skin, etc.
The color of human skin is mainly determined by the content and distribution of melanin. Ultraviolet radiation promotes the synthesis of melanin, darkens the skin, and causes pigmentation, resulting in the appearance of pigmented spots on the skin. Collagen is an important component of skin, contains a large number of hydrophilic groups, has good moisturizing capability and can moisten the skin. The collagen, the elastin and the glycoprotein are interwoven into a net structure, which plays a role in supporting and protecting the skin, can be filled in the dermis and can relieve wrinkles. However, with aging and ultraviolet irradiation, collagen is lost continuously, which causes skin aging and skin problems such as wrinkles and skin sagging. Ultraviolet irradiation induces high expression of matrix metalloproteinase, promotes collagen decomposition, induces fibroblast apoptosis, and is mainly synthesized by fibroblasts, resulting in reduced collagen synthesis. Free radicals are small molecular substances produced by human metabolism, and it is normal that the human body contains a small amount of free radicals. However, the aging of the skin is caused by excessive accumulation of free radicals in the skin tissue due to external factors or internal factors such as aging, ultraviolet irradiation, environmental pollution, unhealthy living habits, etc., and the skin tissue and cells are damaged. Free radicals are unpaired electronic compounds that are reactive in nature and can damage any cells or tissues with which they come into contact. The free radicals attack the collagen fibers and destroy the structure, so that the collagen fibers lose the original functions. The free radicals have strong oxidizing ability, can oxidize unsaturated fats in cell membranes to form lipid peroxide, generate malondialdehyde, and enable substances such as proteins, nucleic acid lipids and the like to be cross-linked and polymerized to form insoluble substances, and the biological membranes are hardened to reduce permeability, influence substance exchange and finally cause cell death. Free radicals also attack cellular DNA, causing base modifications, base losses, DNA breaks or cross-links, resulting in genetic mutations, aberrations or canceration of skin cells. With the increase of age and overwork, the metabolism function of the skin gradually declines, the generated waste can not be effectively discharged and gradually accumulated, and the skin cells are damaged. Promoting blood circulation, making skin cells obtain sufficient oxygen and nutrients, facilitating waste discharge, and enhancing cell regeneration ability. Therefore, in order to solve the problems caused by skin aging, it is necessary to perform various processes such as inhibiting melanin formation, scavenging free radicals, promoting collagen synthesis, and promoting blood circulation. However, most of the existing anti-aging cosmetics only aim at eliminating free radicals and do not comprehensively resist aging from multiple aspects.
Melanin is produced by melanosomes located within the melanocytes of the basal layer of the epidermis. The melanin synthesis is divided into two stages, the first stage is that tyrosine generates L-dihydroxyphenylalanine under the catalytic action of tyrosinase and further generates dopaquinone under the action of tyrosinase. In the second stage, when cysteine or glutathione exists, the dopaquinone reacts with the cysteine or the glutathione to generate cysteinyl dopa or glutathione dopa, and then the dopaquinone is further subjected to oxidative polymerization to generate the pheomelanin; when the two do not exist, the dopaquinone is cyclized to form dopachrome, if the dopachrome is spontaneously decarboxylated, 5, 6-Dihydroxyindole (DHI) is formed, and the dopachrome is further subjected to oxidative polymerization under the action of tyrosinase to form melanin (DHI melanin); if the DOPAchrome is converted into DHICA by tautomerism under the action of TRP-2, melanin (DHICA melanin) is generated under the action of TRP-1. Melanin is transferred from the melanocyte dendritic tip to keratinocytes after its formation. Therefore, the whitening agent generally has one or more of the following functions: 1. inhibiting melanocyte proliferation, 2 inhibiting melanin formation, 3 inhibiting transfer of melanin granules to keratin cells, 4 accelerating transfer of keratin cells to stratum corneum, and 5 reducing the influence of exogenous factors such as ultraviolet rays. However, the existing common whitening agents have some defects, such as unstable vitamin C, safety of arbutin and slow tyrosinase inhibition effect. Kojic acid has obvious whitening and freckle removing effects but certain toxicity. These whitening agents have disadvantages such as unstable effects or irritation and side effects to the skin. Free radicals are produced by the human body and are generally in dynamic equilibrium within the body. The external or internal cause breaks the balance, so that the free radicals are excessively accumulated, and the free radicals can cause damage to cells and tissues. The free radical is generated by phagocytes, redox cycle, xanthine oxidase, and the like. The existing commonly used free radical scavengers include enzyme free radical scavengers, vitamin free radical scavengers and polyphenol free radical scavengers. However, the activities of the enzyme free radical scavenger and the vitamin free radical scavenger are unstable and are easily affected by external factors. The polyphenol free radical scavenger is not easy to be absorbed by skin due to the existence of stratum corneum of the skin. Collagen is a macromolecular substance, and the collagen cannot be effectively supplemented to a human body by smearing or taking the collagen due to the barrier of the skin cuticle and the digestion of intestines and stomach.
Disclosure of Invention
The present invention aims to provide a polypeptide and plant composition for inhibiting melanin synthesis and a preparation method thereof, so as to solve the problems in the background technology.
The invention provides a polypeptide for inhibiting melanin synthesis and a plant composition, which are prepared from a plurality of polypeptides and plant extract combinations of a polypeptide for inhibiting melanin synthesis, a polypeptide for scavenging in vivo free radicals, a polypeptide for promoting collagen synthesis, a polypeptide for promoting fibroblast proliferation, a polypeptide for blocking nerve signal transmission, a plant extract for inhibiting tyrosinase activity, a plant extract for scavenging free radicals, a plant extract for promoting collagen synthesis, a plant extract for promoting skin cell proliferation and division and a plant extract for promoting skin to absorb active substances, wherein the polypeptides and the plant extract combinations are as follows:
(1) the polypeptide that inhibits melanin synthesis may be one or more polypeptides selected from the group consisting of: nonapeptide-1, tetrapeptide-30;
(2) the polypeptide that scavenges free radicals in vivo may be one or more polypeptides selected from the group consisting of: l-carnosine, decapeptide-12, glutathione;
(3) the polypeptide that promotes collagen synthesis may be one or more polypeptides selected from the group consisting of: palmitoyl pentapeptide-4, palmitoyl tripeptide-1, palmitoyl tetrapeptide-7, palmitoyl tripeptide-55, pentapeptide-18, acetyl tetrapeptide-9;
(4) the polypeptide that promotes fibroblast proliferation may be one or more polypeptides selected from the group consisting of: hexapeptide-9;
(5) the polypeptide that blocks neural signaling may be one or more polypeptides selected from the group consisting of: acetyl hexapeptide-8, pentapeptide-3;
the various plant extracts are as follows:
(A) the plant extract for inhibiting tyrosinase activity is Coicis semen extract;
(B) the plant extract for scavenging free radicals is herba Cynomorii extract;
(C) the plant extract for promoting collagen synthesis is radix astragali extract;
(D) the plant extract for promoting skin cell proliferation and division is bupleuri radix extract;
(E) the plant extract for promoting skin absorption of active substances is Glycyrrhrizae radix extract;
as a further scheme of the invention: the actual polypeptide combination is: palmitoyl pentapeptide-4, palmitoyl tripeptide-1, palmitoyl tetrapeptide-7, palmitoyl tripeptide-5, nonapeptide-1, L-carnosine, hexapeptide-9, acetyl hexapeptide-8 and pentapeptide-3, wherein the mass fraction of the polypeptide is 0.001-0.5%.
As a further scheme of the invention: the mass percentage of each component of the polypeptide is 0.005 percent of palmitoyl pentapeptide-4, 0.005 percent of palmitoyl tripeptide-1, 0.0025 percent of palmitoyl tetrapeptide-7, 0.005 percent of palmitoyl tripeptide-5, 0.01 percent of nonapeptide-1, 0.5 percent of L-carnosine, 0.05 percent of hexapeptide-9, 0.2 percent of acetyl hexapeptide-8 and 0.01 percent of pentapeptide-3 respectively.
As a further scheme of the scheme: the actual plant extract composition is as follows: coix seed extract, cynomorium songaricum extract, astragalus extract, radix bupleuri extract and liquorice extract, wherein the mass fraction of the plant extracts is 0.01-1%.
As a further scheme of the invention: the mass percentage of each component of the plant extract is 0.2 percent.
As a further scheme of the invention: the solvent humectant comprises pure water, glycerol and butanediol, and the mass fraction of the solvent humectant is 0.5-70%.
As a further scheme of the invention: also comprises a preservative which is phenoxyethanol, and the mass fraction of the preservative is 0.5-1%.
As a further scheme of the invention: the pH regulator is acetic acid and lactic acid, and the mass fraction of the pH regulator is 0.01-1%.
As a further scheme of the invention: in step 3, the PH adjusting agent is one of acetic acid or lactic acid, preferably acetic acid.
As a further scheme of the invention: the composition comprises the following components in percentage by mass: 25% of pure water, 0.5% of glycerol, 70% of butanediol, 201% of tween-1, 1% of phenoxyethanol and 0.5% of acetic acid.
The present invention also includes a method of preparing a polypeptide plant extract composition, the method comprising the steps of:
step 1: mixing, grinding and dissolving the prepared indissoluble polypeptide, water, glycerol and butanediol to prepare a component A;
step 2: adding a prepared amount of plant extract into water, stirring uniformly, heating to 80-85 ℃, keeping the temperature, stirring, naturally cooling, adding water-soluble polypeptide, stirring and dissolving to obtain a component B;
and step 3: adding the component B into the component A, stirring, adding antiseptic, stirring, adding pH regulator, and regulating pH to 4.5-7.0 to obtain extract.
As a further scheme of the invention: in the step 2, the heat preservation stirring time is 20-30 min.
As a further scheme of the invention: in step 2, the B component should be cooled to below 40 ℃.
The invention has the technical effects and advantages that:
1. the polypeptide can effectively inhibit the synthesis of melanin, and after the polypeptide and the plant extract are mixed for use, the inhibition effect is more obvious than that of a single component, so that the synergistic effect exists between the polypeptide and the plant extract, the formation of melanin can be better inhibited, and the pigmentation can be prevented.
2. The polypeptide and the plant extract have the function of scavenging free radicals, but the plant extract has stronger scavenging effect on the free radicals than the polypeptide, and the polypeptide and the plant extract have synergistic action, so that the scavenging effect of the polypeptide and the plant extract in mixed use is stronger than that of the polypeptide and the plant extract in single use.
3. The promotion effect of the polypeptide and the plant extract after being mixed is higher than that of a single component, and the polypeptide and the plant extract have a synergistic effect, so that the synthesis of collagen can be synergistically promoted from different aspects, and the content of the collagen in skin is remarkably increased.
4. The polypeptide and the plant extract have synergistic effect, and the promotion effect on fibroblast proliferation is improved along with the increase of the types of the polypeptide and the addition of the plant extract. The anti-aging effect is more comprehensive by resisting aging from multiple aspects. The polypeptide component and the plant extract have synergistic effect and are more efficient. Meanwhile, the polypeptide is very safe, has homologous polypeptide components with human bodies, and is not easy to cause immune reaction and other side effects of the human bodies.
Detailed Description
The technical solutions in the embodiments of the present invention will be clearly and completely described below with reference to the embodiments of the present invention, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all of the embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
Example one
A polypeptide and plant composition for inhibiting melanin synthesis is characterized by comprising the following components:
(A) palmitoyl pentapeptide-4 at a level of 0.005% by weight of the composition;
(B) palmitoyl tetrapeptide-7 at a level of 0.0025% by weight of the composition;
(C) preservative accounting for 1 percent of the weight of the composition;
(D) a pH regulator in an amount of 0.5% by weight of the composition;
(E) glycerin accounting for 0.4-0.6% of the weight of the composition;
(F) 70% by weight of the composition of butylene glycol;
(G) the balance of water.
A method for preparing polypeptide and plant composition for inhibiting melanin synthesis comprises the following steps:
step 1: mixing, grinding and dissolving a prepared amount of palmitoyl pentapeptide-4, palmitoyl tetrapeptide-7, glycerol and butanediol to prepare a component A;
step 2: adding the component B into the component A, uniformly stirring, adding phenoxyethanol, uniformly stirring, and adding acetic acid to adjust the pH value to be between 5.5 and 6.5.
Example two
A polypeptide and plant composition for inhibiting melanin synthesis is characterized by comprising the following components:
(A) palmitoyl pentapeptide-4 at a level of 0.005% by weight of the composition;
(B) palmitoyl tripeptide-1 in an amount of 0.005% by weight of the composition;
(C) palmitoyl tetrapeptide-7 at a level of 0.0025% by weight of the composition;
(D) palmitoyl tripeptide-5 in an amount of 0.005% by weight of the composition;
(E) preservative accounting for 1 percent of the weight of the composition;
(F) a pH regulator in an amount of 0.5% by weight of the composition;
(G) glycerin accounting for 0.4-0.6% of the weight of the composition;
(H) 70% by weight of the composition of butylene glycol;
(I) the balance of water.
A method for preparing polypeptide and plant composition for inhibiting melanin synthesis comprises the following steps:
step 1: mixing, grinding and dissolving a prepared amount of palmitoyl pentapeptide-4, palmitoyl tetrapeptide-7, palmitoyl tripeptide-1, palmitoyl tripeptide-5, glycerol and butanediol to obtain component A,
step 2: adding the component B into the component A, uniformly stirring, adding phenoxyethanol, uniformly stirring, and adding acetic acid to adjust the pH value to be between 5.5 and 6.5.
EXAMPLE III
A polypeptide and plant composition for inhibiting melanin synthesis is characterized by comprising the following components:
(A) palmitoyl pentapeptide-4 at a level of 0.005% by weight of the composition;
(B) palmitoyl tripeptide-1 in an amount of 0.005% by weight of the composition;
(C) palmitoyl tetrapeptide-7 at a level of 0.0025% by weight of the composition;
(D) palmitoyl tripeptide-5 in an amount of 0.005% by weight of the composition;
(E) hexapeptide-9 in an amount of 0.05% by weight of the composition;
(F) preservative accounting for 1 percent of the weight of the composition;
(G) a pH regulator in an amount of 0.5% by weight of the composition;
(H) glycerin accounting for 0.4-0.6% of the weight of the composition;
(I) 70% by weight of the composition of butylene glycol;
(J) the balance of water.
A method for preparing polypeptide and plant composition for inhibiting melanin synthesis comprises the following steps:
step 1: mixing, grinding and dissolving a prepared amount of palmitoyl pentapeptide-4, palmitoyl tetrapeptide-7, palmitoyl tripeptide-1, palmitoyl tripeptide-5, glycerol and butanediol to prepare a component A;
step 2: dissolving hexapeptide-9 in pure water as component B, adding component B into component A, stirring, adding phenoxyethanol, stirring, and adding acetic acid to adjust pH to 5.5-6.5.
Example four
A polypeptide and plant composition for inhibiting melanin synthesis is characterized by comprising the following components:
(A) palmitoyl pentapeptide-4 at a level of 0.005% by weight of the composition;
(B) palmitoyl tripeptide-1 in an amount of 0.005% by weight of the composition;
(C) palmitoyl tetrapeptide-7 at a level of 0.0025% by weight of the composition;
(D) palmitoyl tripeptide-5 in an amount of 0.005% by weight of the composition;
(E) l-carnosine at 0.5% by weight of the composition;
(F) hexapeptide-9 in an amount of 0.05% by weight of the composition;
(G) preservative accounting for 1 percent of the weight of the composition;
(H) a pH regulator in an amount of 0.5% by weight of the composition;
(I) glycerin accounting for 0.4-0.6% of the weight of the composition;
(J) 70% by weight of the composition of butylene glycol;
(K) the balance of water.
A method for preparing polypeptide and plant composition for inhibiting melanin synthesis comprises the following steps:
step 1: mixing, grinding and dissolving a prepared amount of palmitoyl pentapeptide-4, palmitoyl tetrapeptide-7, palmitoyl tripeptide-1, palmitoyl tripeptide-5, glycerol and butanediol to prepare a component A;
step 2: dissolving hexapeptide-9 and L-carnosine in pure water as component B, adding component B into component A, stirring, adding phenoxyethanol, stirring, and adding acetic acid to adjust pH to 5.5-6.5.
EXAMPLE five
A polypeptide and plant composition for inhibiting melanin synthesis is characterized by comprising the following components:
(A) palmitoyl pentapeptide-4 at a level of 0.005% by weight of the composition;
(B) palmitoyl tripeptide-1 in an amount of 0.005% by weight of the composition;
(C) palmitoyl tetrapeptide-7 at a level of 0.0025% by weight of the composition;
(D) palmitoyl tripeptide-5 in an amount of 0.005% by weight of the composition;
(E) nonapeptide-1 in an amount of 0.01% by weight of the composition;
(F) l-carnosine at 0.5% by weight of the composition;
(G) hexapeptide-9 in an amount of 0.05% by weight of the composition;
(H) preservative accounting for 1 percent of the weight of the composition;
(I) a pH regulator in an amount of 0.5% by weight of the composition;
(J) glycerin accounting for 0.4-0.6% of the weight of the composition;
(K) 70% by weight of the composition of butylene glycol;
(L) the balance of water.
A method for preparing polypeptide and plant composition for inhibiting melanin synthesis comprises the following steps:
step 1: mixing, grinding and dissolving a prepared amount of palmitoyl pentapeptide-4, palmitoyl tetrapeptide-7, palmitoyl tripeptide-1, palmitoyl tripeptide-5, glycerol and butanediol to prepare a component A;
step 2: dissolving hexapeptide-9, L-carnosine and nonapeptide-1 in pure water as component B, adding component B into component A, stirring, adding phenoxyethanol, stirring, and adding acetic acid to adjust pH to 5.5-6.5.
EXAMPLE six
A polypeptide and plant composition for inhibiting melanin synthesis is characterized by comprising the following components:
(A) palmitoyl pentapeptide-4 at a level of 0.005% by weight of the composition;
(B) palmitoyl tripeptide-1 in an amount of 0.005% by weight of the composition;
(C) palmitoyl tetrapeptide-7 at a level of 0.0025% by weight of the composition;
(D) palmitoyl tripeptide-5 in an amount of 0.005% by weight of the composition;
(E) nonapeptide-1 in an amount of 0.01% by weight of the composition;
(F) l-carnosine at 0.5% by weight of the composition;
(G) hexapeptide-9 in an amount of 0.05% by weight of the composition;
(H) acetyl hexapeptide-8 accounting for 0.2 percent of the weight of the composition;
(I) pentapeptide-3 in 0.01 wt% of the composition;
(J) preservative accounting for 1 percent of the weight of the composition;
(K) a pH regulator in an amount of 0.5% by weight of the composition;
(L) 0.4-0.6% by weight of the composition of glycerol;
(M) butylene glycol at 70% by weight of the composition;
(N) the balance of water.
A method for preparing polypeptide and plant composition for inhibiting melanin synthesis comprises the following steps:
step 1: mixing, grinding and dissolving a prepared amount of palmitoyl pentapeptide-4, palmitoyl tetrapeptide-7, palmitoyl tripeptide-1, palmitoyl tripeptide-5, glycerol and butanediol to prepare a component A;
step 2: hexapeptide-9, L-carnosine, nonapeptide-1, acetyl hexapeptide-8 and pentapeptide-3 are dissolved in pure water as a component B; and step 3: adding the component B into the component A, stirring uniformly, adding phenoxyethanol, stirring uniformly, and adding acetic acid to adjust the pH value to be between 5.5 and 6.5.
EXAMPLE seven
A polypeptide and plant composition for inhibiting melanin synthesis is characterized by comprising the following components:
(A) palmitoyl pentapeptide-4 at a level of 0.005% by weight of the composition;
(B) palmitoyl tripeptide-1 in an amount of 0.005% by weight of the composition;
(C) palmitoyl tetrapeptide-7 at a level of 0.0025% by weight of the composition;
(D) palmitoyl tripeptide-5 in an amount of 0.005% by weight of the composition;
(E) nonapeptide-1 in an amount of 0.01% by weight of the composition;
(F) l-carnosine at 0.5% by weight of the composition;
(G) hexapeptide-9 in an amount of 0.05% by weight of the composition;
(H) acetyl hexapeptide-8 accounting for 0.2 percent of the weight of the composition;
(I) pentapeptide-3 in 0.01 wt% of the composition;
(J) 0.2% by weight of the composition of an extract of coix seed;
(K) preservative accounting for 1 percent of the weight of the composition;
(L) a PH adjusting agent at 0.5% by weight of the composition;
(M) 0.4-0.6% by weight of the composition of glycerol;
(N) butylene glycol at 70% by weight of the composition;
(0) the balance of water.
A method for preparing polypeptide and plant composition for inhibiting melanin synthesis comprises the following steps:
step 1: mixing, grinding and dissolving a prepared amount of palmitoyl pentapeptide-4, palmitoyl tetrapeptide-7, palmitoyl tripeptide-1, palmitoyl tripeptide-5, glycerol and butanediol to prepare a component A;
step 2: adding Coicis semen (Coix LACRYMA-JOBI) extract into water, stirring, heating to 80-85 deg.C, stirring for 20-30min, naturally cooling to below 40 deg.C, adding hexapeptide-9, L-carnosine, nonapeptide-1, acetyl hexapeptide-8, and pentapeptide-3, stirring, and dissolving to obtain component B;
and step 3: adding the component B into the component A, stirring uniformly, adding phenoxyethanol, stirring uniformly, and adding acetic acid to adjust the pH value to about 5.5.
Example eight
A polypeptide and plant composition for inhibiting melanin synthesis is characterized by comprising the following components:
(A) palmitoyl pentapeptide-4 at a level of 0.005% by weight of the composition;
(B) palmitoyl tripeptide-1 in an amount of 0.005% by weight of the composition;
(C) palmitoyl tetrapeptide-7 at a level of 0.0025% by weight of the composition;
(D) palmitoyl tripeptide-5 in an amount of 0.005% by weight of the composition;
(E) nonapeptide-1 in an amount of 0.01% by weight of the composition;
(F) l-carnosine at 0.5% by weight of the composition;
(G) hexapeptide-9 in an amount of 0.05% by weight of the composition;
(H) acetyl hexapeptide-8 accounting for 0.2 percent of the weight of the composition;
(I) pentapeptide-3 in 0.01 wt% of the composition;
(J) semen Coicis extract and herba Cynomorii extract 0.2 wt%;
(K) preservative accounting for 1 percent of the weight of the composition;
(L) a PH adjusting agent at 0.5% by weight of the composition;
(M) 0.4-0.6% by weight of the composition of glycerol;
(N) butylene glycol at 70% by weight of the composition;
(0) the balance of water.
A method for preparing polypeptide and plant composition for inhibiting melanin synthesis comprises the following steps:
step 1: mixing, grinding and dissolving a prepared amount of palmitoyl pentapeptide-4, palmitoyl tetrapeptide-7, palmitoyl tripeptide-1, palmitoyl tripeptide-5, glycerol and butanediol to prepare a component A;
step 2: adding Coicis semen (Coix LACRYMA-JOBI) extract and herba Cynomorii (Cynomorium SONGARICUM) extract into water, stirring, heating to 80-85 deg.C, stirring for 20-30min, naturally cooling to below 40 deg.C, adding hexapeptide-9, L-carnosine, nonapeptide-1, acetyl hexapeptide-8, and pentapeptide-3, stirring, and dissolving to obtain component B;
and step 3: adding the component B into the component A, stirring uniformly, adding phenoxyethanol, stirring uniformly, and adding acetic acid to adjust the pH value to about 5.5.
Example nine
A polypeptide and plant composition for inhibiting melanin synthesis is characterized by comprising the following components:
(A) palmitoyl pentapeptide-4 at a level of 0.005% by weight of the composition;
(B) palmitoyl tripeptide-1 in an amount of 0.005% by weight of the composition;
(C) palmitoyl tetrapeptide-7 at a level of 0.0025% by weight of the composition;
(D) palmitoyl tripeptide-5 in an amount of 0.005% by weight of the composition;
(E) nonapeptide-1 in an amount of 0.01% by weight of the composition;
(F) l-carnosine at 0.5% by weight of the composition;
(G) hexapeptide-9 in an amount of 0.05% by weight of the composition;
(H) acetyl hexapeptide-8 accounting for 0.2 percent of the weight of the composition;
(I) pentapeptide-3 in 0.01 wt% of the composition;
(J) coix seed extract, cynomorium songaricum extract and astragalus extract accounting for 0.2 percent of the weight of the composition;
(K) preservative accounting for 1 percent of the weight of the composition;
(L) a PH adjusting agent at 0.5% by weight of the composition;
(M) 0.4-0.6% by weight of the composition of glycerol;
(N) butylene glycol at 70% by weight of the composition;
(0) the balance of water.
A method for preparing polypeptide and plant composition for inhibiting melanin synthesis comprises the following steps:
step 1: mixing, grinding and dissolving a prepared amount of palmitoyl pentapeptide-4, palmitoyl tetrapeptide-7, palmitoyl tripeptide-1, palmitoyl tripeptide-5, glycerol and butanediol to prepare a component A;
step 2: adding Coicis semen (Coix LACRYMA-JOBI) extract, herba Cynomorii (Cynomorium SONGARICUM) extract, and radix astragali (Astragalus) extract into water, stirring, heating to 80-85 deg.C, stirring for 20-30min, naturally cooling to below 40 deg.C, adding hexapeptide-9, L-carnosine, nonapeptide-1, acetyl hexapeptide-8, and pentapeptide-3, stirring, and dissolving to obtain component B;
and step 3: adding the component B into the component A, stirring uniformly, adding phenoxyethanol, stirring uniformly, and adding acetic acid to adjust the pH value to about 5.5.
The eleven polypeptide and plant compositions for inhibiting melanin synthesis are characterized by comprising the following components:
(A) palmitoyl pentapeptide-4 at a level of 0.005% by weight of the composition;
(B) palmitoyl tripeptide-1 in an amount of 0.005% by weight of the composition;
(C) palmitoyl tetrapeptide-7 at a level of 0.0025% by weight of the composition;
(D) palmitoyl tripeptide-5 in an amount of 0.005% by weight of the composition;
(E) nonapeptide-1 in an amount of 0.01% by weight of the composition;
(F) l-carnosine at 0.5% by weight of the composition;
(G) hexapeptide-9 in an amount of 0.05% by weight of the composition;
(H) acetyl hexapeptide-8 accounting for 0.2 percent of the weight of the composition;
(I) pentapeptide-3 in 0.01 wt% of the composition;
(J) coix seed extract, cynomorium songaricum extract, astragalus extract and bupleurum extract accounting for 0.2 percent of the weight of the composition;
(K) preservative accounting for 1 percent of the weight of the composition;
(L) a PH adjusting agent at 0.5% by weight of the composition;
(M) 0.4-0.6% by weight of the composition of glycerol;
(N) butylene glycol at 70% by weight of the composition;
(0) the balance of water.
A method for preparing polypeptide and plant composition for inhibiting melanin synthesis comprises the following steps:
step 1: mixing, grinding and dissolving a prepared amount of palmitoyl pentapeptide-4, palmitoyl tetrapeptide-7, palmitoyl tripeptide-1, palmitoyl tripeptide-5, glycerol and butanediol to prepare a component A;
and step 3: adding Coicis semen (Coix LACRYMA-JOBI) extract, herba Cynomorii (Cynomorium SONGARICUM) extract, and radix astragali (Astragalus) extract into water, stirring, heating to 80-85 deg.C, stirring for 20-30min, naturally cooling to below 40 deg.C, adding hexapeptide-9, L-carnosine, nonapeptide-1, acetyl hexapeptide-8, and pentapeptide-3, stirring, and dissolving to obtain component B;
and step 3: adding the component B into the component A, stirring uniformly, adding phenoxyethanol, stirring uniformly, and adding acetic acid to adjust the pH value to about 5.5.
EXAMPLE eleven
A polypeptide and plant composition for inhibiting melanin synthesis is characterized by comprising the following components:
(A) palmitoyl pentapeptide-4 at a level of 0.005% by weight of the composition;
(B) palmitoyl tripeptide-1 in an amount of 0.005% by weight of the composition;
(C) palmitoyl tetrapeptide-7 at a level of 0.0025% by weight of the composition;
(D) palmitoyl tripeptide-5 in an amount of 0.005% by weight of the composition;
(E) nonapeptide-1 in an amount of 0.01% by weight of the composition;
(F) l-carnosine at 0.5% by weight of the composition;
(G) hexapeptide-9 in an amount of 0.05% by weight of the composition;
(H) acetyl hexapeptide-8 accounting for 0.2 percent of the weight of the composition;
(I) pentapeptide-3 in 0.01 wt% of the composition;
(J) coix seed extract, cynomorium songaricum extract, astragalus extract, bupleurum extract and liquorice extract accounting for 0.2 percent of the weight of the composition;
(K) preservative accounting for 1 percent of the weight of the composition;
(L) a PH adjusting agent at 0.5% by weight of the composition;
(M) 0.4-0.6% by weight of the composition of glycerol;
(N) butylene glycol at 70% by weight of the composition;
(0) the balance of water.
A method for preparing polypeptide and plant composition for inhibiting melanin synthesis comprises the following steps:
step 1: mixing, grinding and dissolving a prepared amount of palmitoyl pentapeptide-4, palmitoyl tetrapeptide-7, palmitoyl tripeptide-1, palmitoyl tripeptide-5, glycerol and butanediol to prepare a component A;
step 2: adding Coicis semen (Coix LACRYMA-JOBI) extract, herba Cynomorii (Cynomorium SONGARICUM) extract, radix astragali (Astragalus) extract, bupleuri radix (Bupleurum chinensis) extract, and Glycyrrhrizae radix (Glycyrrhiza URALENSIS) extract into water, stirring, heating to 80-85 deg.C, stirring for 20-30min, naturally cooling to below 40 deg.C, adding hexapeptide-9, L-carnosine, nonapeptide-1, acetyl hexapeptide-8, and pentapeptide-3, stirring and dissolving to obtain component B;
and step 3: adding the component B into the component A, stirring uniformly, adding phenoxyethanol, stirring uniformly, and adding acetic acid to adjust the pH value to about 5.5.
Example twelve
A polypeptide and plant composition for inhibiting melanin synthesis is characterized by comprising the following components:
(A) coix seed extract, cynomorium songaricum extract, astragalus extract, bupleurum extract and liquorice extract accounting for 0.2 percent of the weight of the composition;
(B) preservative accounting for 1 percent of the weight of the composition;
(C) a pH regulator in an amount of 0.5% by weight of the composition;
(D) glycerin accounting for 0.4-0.6% of the weight of the composition;
(E) 70% by weight of the composition of butylene glycol;
(F) the balance of water.
A method for preparing polypeptide and plant composition for inhibiting melanin synthesis comprises the following steps:
step 1: uniformly mixing a configured amount of glycerol and butanediol to prepare a component A;
step 2: mixing Coicis semen (Coix LACRYMA-JOBI) extract, herba Cynomorii (Cynomorium SONGARICUM) extract, radix astragali (Astragalus) extract, bupleuri radix (Bupleurum chinensis) extract, and Glycyrrhrizae radix (Glycyrrhiza URALENSIS) extract with water, stirring, heating to 80-85 deg.C, stirring for 20-30min, naturally cooling to below 40 deg.C, adding component B into component A, stirring, and making into component B
And step 3: adding the component B into the component A, stirring uniformly, adding phenoxyethanol, stirring uniformly, and adding acetic acid to adjust the pH value to about 5.5.
Wherein:
palmitoyl pentapeptide-4: can penetrate through dermis, stimulate the proliferation of collagen, elastic fiber and hyaluronic acid, improve the moisture content of skin and smooth fine lines;
palmitoyl tripeptide-5: can simulate the sequence of thrombospondin 1, cause the release of active growth factor beta, accelerate the synthesis of collagen, and can inhibit oxygen free radicals and hydroxyl free radicals;
palmitoyl tripeptide-1 is a signal peptide, can regulate the expression of wound healing protein and generate more skin repair protein and collagen;
palmitoyl tetrapeptide-7: is messenger peptide, and can promote the synthesis of collagen and elastin;
pentapeptide-3: can block the release of sodium ions of a postsynaptic membrane of a nerve cell, relax muscles and fade wrinkles;
acetyl hexapeptide-8: can affect the formation of the bubble-melting complex, so that the bubble can not effectively release neurotransmitter, locally block the transmission of nerve signals, relax skin muscles and remove wrinkles;
nonapeptide-1: can reduce the formation of melanin by inhibiting the melanocyte stimulating hormone, thereby achieving the effect of whitening skin;
hexapeptide-9: can increase the synthesis of type I collagen, type IV collagen, laminin-5 and integrin, promote the differentiation and maturation of cells and has comprehensive and obvious anti-wrinkle effect;
carnosine: can effectively remove free radicals, reduce the damage of the free radicals to proteins and cells, and prevent the cross-linking polymerization of macromolecular substances such as proteins, nucleic acid lipids and the like.
Experimental analysis 1: experiment for inhibiting melanin synthesis of melanoma cells
Experimental materials and instruments
Melanoma cell B-16, RPMI1640 medium, trypsin, the compositions of the examples, UV spectrophotometer, NaOH.
Experimental methods
Melanoma cells B-16 were cultured at a cell density of 1 x104Loading in 6-well plate with one/mL cell, adding RPMI1640 medium in 5% CO2Culturing in a carbon dioxide incubator at 37 ℃ for 24h, and then changing the culture solution. The experimental group was added with the medium containing each example, and 5 duplicate wells were set. The control group replaced the sample solution with an equal amount of RPMI1640 medium. After culturing for 3 days, removing the supernatant, adding 1.5mL of 2.5g/L trypsin digestion solution, digesting for 5min at room temperature, adding RPMI1640 culture medium to terminate digestion, and beating into single cell suspension. 0.5mL was counted. The remaining cell suspension was centrifuged at 1500r/min for 10 min. The supernatant was discarded and 1.5mL of a 1mol/L NaOH solution was added. The incubation was carried out in a water bath at 90 ℃ for 2h and the absorbance was measured at 492 nm.
And (3) calculating: inhibition ═ 100% (1- (sample well absorbance value/sample well cell density)/(control well absorbance value/control well cell density)) ×.
Results of the experiment
The results of the experiments are shown in the following table
The experimental result shows that the polypeptide can effectively inhibit the synthesis of melanin, the inhibiting effect is more obvious than that of a single component after the polypeptide and the plant extract are mixed for use, and the synergistic effect exists between the polypeptide and the plant extract, so that the melanin can be better inhibited from being formed, and the pigmentation can be prevented.
Experimental analysis 2: DPPH free radical scavenging experiment
Experimental materials and instruments
Ethanol, DPPH, example compositions, uv spectrophotometer;
experimental methods
Add 2x10 to the tubes respectively-42mL of mol/L DPPH solution, and an experimental group and a control group are arranged. The experimental groups were added to 2mL of each example, and the control group was added with the same amount of control solution instead of the examples, and each group was repeated for 3 groups. A blank control was set, and 2mL of each of the examples and the control were added to the test tube, and 3 groups were repeated. After mixing well and reacting in dark for 30min, the absorbance value is measured at 517 nm.
And (3) calculating: clearance [1- (Ax-A3)/a1] ] 100% [ Ax: measuring absorbance values of the experimental groups; a3: measuring absorbance value of the blank control group; a1: absorbance values were measured for the control group ].
Results of the experiment
The results of the experiments are shown in the following table
The experimental result shows that the polypeptide and the plant extract have the effect of scavenging free radicals, but the plant extract has stronger effect of scavenging free radicals than the polypeptide, and the polypeptide and the plant extract have synergistic action, so that the effect of scavenging the polypeptide and the plant extract by mixing the polypeptide and the plant extract is stronger than that by singly using the polypeptide and the plant extract.
Experimental analysis 3: experiment for promoting collagen production
Experimental materials and instruments
ICR mouse, chloramine T, dimethylaminobenzaldehyde, HYP, diethyl ether, sodium hydroxide, compositions of the examples, uv spectrophotometer;
experimental methods
78 ICR mice are aged for 7-8 weeks, the weight of the mice is 23g +/-2 g, the mice are clean, the mice are divided into male and female halves, the mice are divided into 13 groups according to the weight, and each group comprises 6 mice. The back was depilated, exposing approximately 2cm2 of skin, of which twelve groups of examples one-twelve, and the remaining group was coated with a control containing no active ingredient. Preparation of a standard curve for HYP: 0.01 mg/L HYP standard solution 0, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8 and 0.9mL are respectively taken, added with water to be complemented to 2.0mL, added with 1.0mL chloramine T solution, shaken evenly, placed for 20min at room temperature, added with 1.0mL p-dimethylaminobenzaldehyde solution, taken out in a water bath at 60 ℃ for 15min, cooled with cold water and subjected to color comparison at 560 nm. A standard curve is drawn with the amount of HYP (μ g) as the abscissa and the absorbance (A) as the ordinate. The test sample is applied for 48 days and then killed, the skin of the exposed part is taken immediately after the mouse is killed, subcutaneous fat is scraped off, the test sample is cut into fragments after being sucked dry by ether, 20mg of the test sample is precisely weighed and placed in a 25mL test tube with a plug scale, 2mL of 6mol/L HCl is added and mixed uniformly, after the plug is sealed, acidolysis is carried out at the constant temperature of 125 ℃ for 3h, the test sample is taken out and cooled, the test sample is completely transferred into a 50mL volumetric flask, 2 drops of phenolphthalein indicator is added, the temperature is adjusted to be reddish by 6mol/L of sodium hydroxide, and then water is added to the volume of 50.0 mL. 0.1mL of the stock solution was taken, and water was added to make up to 2.0mL, which was followed by the same standard procedure.
And (3) calculating: c% ═ m1 × 500/1000/m × 100% [ C%: percentage of HYP in the sample; ml: amount of HYP in 0.1mL sample stock (μ g); m 1: sample mass (mg); collagen percentage (HYP percentage/14% ]).
Results of the experiment
Experimental results the following table shows
| Grouping | Content (wt.) |
| Example one | 68.12％ |
| Example two | 70.82％ |
| EXAMPLE III | 71.26％ |
| Example four | 71.61％ |
| EXAMPLE five | 71.93％ |
| EXAMPLE six | 72.23％ |
| EXAMPLE seven | 72.52.％ |
| Example eight | 72.77％ |
| Example nine | 73.03％ |
| Example ten | 73.95％ |
| EXAMPLE eleven | 74.31％ |
| Example twelve | 65.13％ |
| Control group | 63.15％ |
The experimental results show that the collagen synthesis can be promoted in each example, and the promotion effect of the polypeptide and the plant extract after being mixed is higher than that of the single component. The synergistic effect exists between the polypeptide and the plant extract, the synthesis of collagen can be synergistically promoted from different aspects, and the content of the collagen in the skin is obviously increased.
Experimental analysis 4: experiment for promoting fibroblast proliferation
Experimental materials and instruments
Human skin fibroblasts, DMEM medium, fetal bovine serum, dimethyl sulfoxide (DMSO), thiazole blue (MTT), PBS buffer solution, the composition of each embodiment and a full-automatic enzyme standard instrument.
Experimental methods
Taking cells in logarithmic growth phase, digesting with 2.5g/L pancreatin and adjusting cell suspension density to 1 x105one/mL, inoculated into 96-well plates, each well was added 100uL of DMEM medium (containing 5% fetal bovine serum) and the marginal wells were filled with sterile PBS. Placing in 5% CO2Humidity of 95%, culturing in a carbon dioxide incubator at constant temperature of 37 ℃ for 24h, discarding the supernatant, adding 100uL of DMEM medium containing each example, each example having 6 duplicate wells, and a blank control group without drug. And (3) discarding the supernatant after culturing for 48h, adding 100uL of DMEM culture solution into each well, adding 20uL of MTT solution CO2 culture box with the mass concentration of 5mg/mL, incubating for 4h, discarding the supernatant, adding 100uL of DMSO into each well, shaking on a shaking table for 10min to fully dissolve crystals, and measuring the absorbance A value at 490nm by an enzyme-linked immunosorbent detector.
And (3) calculating: proliferation rate ═ (experimental group a value-control group a value)/control group a value ═ l 00%
Results of the experiment
The results of the experiments are shown in the following table
The experimental results show that the polypeptide has a promoting effect on the proliferation of fibroblasts. There is a synergistic effect between the polypeptide and the plant extract. With the increase of the types of the polypeptides and the addition of the plant extract, the promotion effect on the proliferation of the fibroblasts is improved.
Finally, it should be noted that: although the present invention has been described in detail with reference to the foregoing embodiments, it will be apparent to those skilled in the art that modifications may be made to the embodiments or portions thereof without departing from the spirit and scope of the invention.
Claims (6)
1. A polypeptide and plant composition for inhibiting melanin synthesis is characterized by comprising a plurality of polypeptides and plant extract combinations of a polypeptide for inhibiting melanin synthesis, a polypeptide for scavenging in vivo free radicals, a polypeptide for promoting collagen synthesis, a polypeptide for promoting fibroblast proliferation, a polypeptide for blocking nerve signal transmission, a plant extract for inhibiting tyrosinase activity, a plant extract for scavenging free radicals, a plant extract for promoting collagen synthesis, a plant extract for promoting skin cell proliferation and division and a plant extract for promoting skin to absorb active substances, wherein the polypeptides and the plant extract combinations are as follows:
(1) the polypeptide that inhibits melanin synthesis may be one or more polypeptides selected from the group consisting of: nonapeptide-1, tetrapeptide-30;
(2) the polypeptide that scavenges free radicals in vivo may be one or more polypeptides selected from the group consisting of: l-carnosine, decapeptide-12, glutathione;
(3) the polypeptide that promotes collagen synthesis may be one or more polypeptides selected from the group consisting of: palmitoyl pentapeptide-4, palmitoyl tripeptide-1, palmitoyl tetrapeptide-7, palmitoyl tripeptide-55, pentapeptide-18, acetyl tetrapeptide-9;
(4) the polypeptide that promotes fibroblast proliferation may be one or more polypeptides selected from the group consisting of: hexapeptide-9;
(5) the polypeptide that blocks neural signaling may be one or more polypeptides selected from the group consisting of: acetyl hexapeptide-8, pentapeptide-3;
the various plant extracts are as follows:
(A) the plant extract for inhibiting tyrosinase activity is Coicis semen extract and pericarpium Granati extract;
(B) the plant extract for scavenging free radicals is herba Cynomorii extract and radix Sangusorbae extract;
(C) the plant extract for promoting collagen synthesis is radix astragali extract;
(D) the plant extract for promoting skin cell proliferation and division is bupleuri radix extract;
(E) the plant extract for promoting skin absorption of active substances is Glycyrrhrizae radix extract.
2. The polypeptide and plant composition for inhibiting melanin synthesis according to claim 1, wherein said actual combination of polypeptides is: palmitoyl pentapeptide-4, palmitoyl tripeptide-1, palmitoyl tetrapeptide-7, palmitoyl tripeptide-5, nonapeptide-1, L-carnosine, hexapeptide-9, acetyl hexapeptide-8 and pentapeptide-3, wherein the mass fraction of the polypeptide is 0.001-3%, and the preferred mass fraction of the polypeptide is 0.001-2%.
3. The polypeptide and plant composition for inhibiting melanin synthesis according to claim 1, wherein the actual combination of plant extracts is: the composition comprises 0.01-2% by mass of coix seed extract, 0.01-1.5% by mass of cynomorium songaricum extract, astragalus extract, radix bupleuri extract and licorice extract, and the preferred mass fraction of the plant extract is.
4. The polypeptide and plant composition for inhibiting melanin synthesis according to claim 1, further comprising a solvent humectant, wherein the solvent humectant comprises 0.5-70% by weight of pure water, glycerin and butylene glycol.
5. The polypeptide and plant composition for inhibiting melanin synthesis according to claim 1, further comprising a preservative, wherein the preservative is phenoxyethanol, and the mass fraction of the preservative is 0.5-1%.
6. The polypeptide and plant composition for inhibiting melanin synthesis according to claim 1, further comprising a pH regulator, wherein the pH regulator is acetic acid or lactic acid, and the weight percentage of the pH regulator is 0.01-1%.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110053395.1A CN112826778A (en) | 2021-01-15 | 2021-01-15 | Polypeptide and plant composition for inhibiting melanin synthesis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110053395.1A CN112826778A (en) | 2021-01-15 | 2021-01-15 | Polypeptide and plant composition for inhibiting melanin synthesis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112826778A true CN112826778A (en) | 2021-05-25 |
Family
ID=75928215
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110053395.1A Pending CN112826778A (en) | 2021-01-15 | 2021-01-15 | Polypeptide and plant composition for inhibiting melanin synthesis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112826778A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113368004A (en) * | 2021-06-15 | 2021-09-10 | 郑州三铠化妆品有限公司 | Polypeptide composition with anti-aging and repairing effects and preparation method and application thereof |
| CN116162135A (en) * | 2022-01-25 | 2023-05-26 | 上海中翊日化有限公司 | Cyclic peptides with excellent performance and application thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108852894A (en) * | 2018-06-13 | 2018-11-23 | 浙江湃肽生物有限公司 | It is a kind of for repairing the polypeptides in combination of whitening wrinkle-removing |
| CN111529427A (en) * | 2020-06-15 | 2020-08-14 | 溯源生命科技股份有限公司 | Active polypeptide compound plant extract anti-aging repair composition, application and essence milk containing composition |
-
2021
- 2021-01-15 CN CN202110053395.1A patent/CN112826778A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108852894A (en) * | 2018-06-13 | 2018-11-23 | 浙江湃肽生物有限公司 | It is a kind of for repairing the polypeptides in combination of whitening wrinkle-removing |
| CN111529427A (en) * | 2020-06-15 | 2020-08-14 | 溯源生命科技股份有限公司 | Active polypeptide compound plant extract anti-aging repair composition, application and essence milk containing composition |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113368004A (en) * | 2021-06-15 | 2021-09-10 | 郑州三铠化妆品有限公司 | Polypeptide composition with anti-aging and repairing effects and preparation method and application thereof |
| CN113368004B (en) * | 2021-06-15 | 2022-07-29 | 郑州三铠化妆品有限公司 | Polypeptide composition with anti-aging and repairing effects and preparation method and application thereof |
| CN116162135A (en) * | 2022-01-25 | 2023-05-26 | 上海中翊日化有限公司 | Cyclic peptides with excellent performance and application thereof |
| CN116162135B (en) * | 2022-01-25 | 2023-09-26 | 上海中翊日化有限公司 | Cyclic peptides with excellent performance and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111603406A (en) | Cosmetic composition containing penetration enhancer, essence and preparation method thereof | |
| CN111514056B (en) | Polypeptide composition with melanin generation promoting effect and application thereof | |
| CN111067835A (en) | Whitening composition for resisting skin saccharification reaction and preparation method thereof | |
| CN112826778A (en) | Polypeptide and plant composition for inhibiting melanin synthesis | |
| CN113576975B (en) | Easily-absorbed anti-aging composition and preparation method and application thereof | |
| CN108670933B (en) | Skin care composition with moisturizing, whitening and anti-aging functions and application thereof | |
| CN108434443A (en) | A kind of whitening antioxidation composition and application thereof | |
| CN109771351A (en) | A kind of Whitening, spot composition and its application | |
| CN112156062A (en) | Composition with anti-inflammatory and repairing activity and essence containing composition | |
| CN113425639A (en) | Antioxidant composition, application thereof and product | |
| KR101727788B1 (en) | Sargassum thunbergii hydrolysates that have high glucuronic acid cotent, preparation method thereof and antiaging cosmetic composition containing the same | |
| CN111265441A (en) | Composition capable of enhancing skin night repair and regeneration capacity and application thereof | |
| CN110302128A (en) | A kind of whitening antiallergic rich in natural product extraction ingredient is releived sleep mask and preparation method thereof | |
| KR20030024932A (en) | Cosmetic composition containing centella asiatica extracts | |
| CN112891243A (en) | Cosmetic containing anti-wrinkle composition and preparation method thereof | |
| CN109846798B (en) | Composition for tightening skin and cosmetic containing same | |
| TW201700108A (en) | Phalaenopsis extract for whitening skin and resisting skin aging capable of reducing the activity of tyrosinase and being anti-oxidative , capable of whitening the skin and slowing down the phenomenon of skin aging | |
| CN112656701A (en) | Whitening and freckle-removing composition containing PDRN and application thereof | |
| KR101803757B1 (en) | Cosmetic composition containing natural complex fermented extracts | |
| CN111568781A (en) | Skin care gel and preparation method thereof | |
| CN111700836A (en) | Composition capable of improving skin color and whitening skin and skin care product containing composition | |
| CN110585079A (en) | Radiation-resistant composition containing food-borne peptide and radiation-resistant emulsion thereof | |
| CN109833276A (en) | A kind of whitening mask and preparation method thereof | |
| CN115869230A (en) | Anti-wrinkle cosmetic and preparation method thereof | |
| CN109125189A (en) | A kind of inclusion enclave Essence and preparation method thereof of the instant bright color of energy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210525 |